CRSP - CRISPR CMO who resigned after Casgevy approval lands at Takeda
2024-02-02 17:11:18 ET
More on CRISPR Therapeutics, Takeda Pharmaceutical, etc.
- Takeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Call Transcript
- Crispr Therapeutics: Investors Bet Against Casgevy Uptake
- Biotech And Pharma Diversification Pays Off
- Protagonist Therapeutics stock rises on Takeda license deal
- Takeda Pharmaceutical gets new CFO